RGL-2102
/ Shanghai Regenelead Therapies
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2025
To evaluate the efficacy and safety of RGL-2102 for injection in patients with critical limb ischemia as a randomized, double-blind, multi-dose, placebo-controlled Phase II clinical trial
(ChiCTR)
- P2 | N=200 | Recruiting | Sponsor: Zhongshan Hospital Affiliated to Fudan University; Guangzhou Ruiling Pharmaceutical Co., LTD
New P2 trial • Cardiovascular • Peripheral Arterial Disease
1 to 1
Of
1
Go to page
1